21 Jun 2024 --- Novonesis’ Capital Markets Day provided insights on the company’s strategy in capturing the accelerating organic sales growth, upgraded to the upper end of the 5-7% range and the increase of the pro forma adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin to 35-36%.
